What is the current Price Target for the Regulus Therapeutics Inc. stock?

The average Regulus Therapeutics Inc. target price is $10.83. This is 501.85% higher than the current stock price. The highest price target is 1,455.56%, the lowest is 233.33%. 6 Analysts have issued a price target Regulus Therapeutics Inc. 2026 .

How high will the Regulus Therapeutics Inc. stock rise?

No reliable answer can be given as to how high the Regulus Therapeutics Inc. stock will rise. The performance of stocks, including the Regulus Therapeutics Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Regulus Therapeutics Inc. stock today?

The performance of Regulus Therapeutics Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Regulus Therapeutics Inc. stock fall?

The decline in Regulus Therapeutics Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Regulus Therapeutics Inc. Forecast, price target & analysts

$1.71

5.28% today

Nasdaq, Apr 04, 07:47 pm CET

ISIN

US75915K1016

Symbol

RGLS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Regulus Therapeutics Inc. Target price 2025 - Analyst rating & recommendation

Regulus Therapeutics Inc. Classifications & Recommendation:

Buy

100%

Regulus Therapeutics Inc. Price Target

Target Price	$10.83
Price	$1.80
Potential	501.85% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target Regulus Therapeutics Inc. 2026 . The average Regulus Therapeutics Inc. target price is $10.83. This is 501.85% register free of charge higher than the current stock price. The highest price target is $28.00 1,455.56% register free of charge , the lowest is $6.00 233.33% register free of charge .
	A rating was issued by 6 analysts: 6 Analysts recommend Regulus Therapeutics Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Regulus Therapeutics Inc. stock has an average upside potential 2026 of 501.85% register free of charge . Most analysts recommend the Regulus Therapeutics Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.82	-1.17
	48.10%	42.68%
P/E		negative

6 Analysts have issued a Regulus Therapeutics Inc. forecast for earnings per share. The average Regulus Therapeutics Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.82	48.10%
2025	$-1.17 42.68% Unlock
2026	$-1.39 18.80% Unlock
2027	$-0.91 34.53% Unlock
2028	$3.78 515.38% Unlock
2029	$6.99 84.92% Unlock

Current	-2.06	13.81%
2025	-1.54 25.24% Unlock
2026	-1.30 15.58% Unlock
2027	-1.97 51.54% Unlock
2028	0.48 124.37% Unlock
2029	0.26 45.83% Unlock

Regulus Therapeutics Inc....

Current Regulus Therapeutics Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Wells Fargo	Locked ➜ Locked	Locked	Mar 27 2025
Canaccord Genuity	Locked ➜ Locked	Locked	Mar 17 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 14 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 26 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 11 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 30 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 08 2024

Analyst Rating	Date
Locked Wells Fargo: Locked ➜ Locked	Mar 27 2025
Locked Canaccord Genuity: Locked ➜ Locked	Mar 17 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 14 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 26 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 11 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 30 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 08 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now